Genetic Technologies to develop most advanced comprehensive risk test

Genetic Technologies announced the development of the Company’s most advanced risk assessment test for serious diseases, building on the success of the Comprehensive Hereditary Breast and Ovarian Cancer test. GeneType’s latest innovation will be a world first; including over 200 high penetrant genes to unlock the hereditary disease risk to its current multi-test associated with the most common cancers, cardiovascular disease, and type 2 diabetes . This ground-breaking innovation enables doctors to identify nearly 100% of people at risk of disease going beyond family history, which is only responsible for 5-15%. Importantly the test includes sporadic non-hereditary disease which is linked to the remaining 85% of people. This population wide test will identify patients at risk of serious disease in nearly 70% of annual mortalities and morbidities and remains a simple non-invasive sample. GeneType is committed to clinically validated innovation advancing its current portfolio offering unparalleled insight into an individual’s risk of serious diseases. This cutting-edge test represents a significant leap forward in personalized preventative healthcare, providing physicians and their patients with an unprecedented tool to tailor interventions and treatment plans.